The study has employed a model of lung cancer in mice, which closely mimics the disease in humans. Treatment with oral PX-478 for five days resulted in significant inhibition of tumor growth, marked reduction in lymph nodes metastases, decreased volume of pleural effusions, and significantly improved survival.
PX-478 was effective in models of both non-small cell lung cancer and small cell lung cancer that express HIF-1 alpha. Enrollment is ongoing in the Phase I dose escalation trial of PX-478 in patients with advanced metastatic cancer and lymphoma. Clinical data from this trial are expected in the second half of 2008.